Despite the limitation of a small cohort of patients (n = 22) and the high rate of treatment discontinuation of the prescribed protocol therapy (17/22), these are the first available prospective data from a pediatric trial in ABL-class fusion positive ALL. Here, ABL1 is linked to acute lymphoblastic leukemia.